Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verona Pharma Plc ADR (NQ: VRNA )

34.98 +1.05 (+3.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Verona Pharma Plc ADR

< Previous 1 2 3 4 Next >
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD. 
Via Investor's Business Daily
Exposures Product Safety
Petco, AppLovin, Dave & Buster's And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug
GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary endpoint, reducing exacerbations significantly over 104 weeks. 
Via Benzinga
Top 3 Health Care Stocks That May Crash In August
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Earnings Preview For Verona Pharma
Via Benzinga
Expert Ratings for Verona Pharma
Via Benzinga
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
VRNA Stock Earnings: Verona Pharma Misses EPS for Q2 2024
VRNA stock results show that Verona Pharma missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Top 3 Health Care Stocks You May Want To Dump This Quarter
Via Benzinga
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales. 
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach. 
Via Benzinga
4 Analysts Have This to Say About Verona Pharma
Via Benzinga
Earnings Preview For Verona Pharma
Via Benzinga
Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
The companies are closing in on the finish line for two new COPD treatments. 
Via Investor's Business Daily
VRNA Stock Earnings: Verona Pharma Misses EPS for Q1 2024
VRNA stock results show that Verona Pharma missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
The healthcare sector is no slouch when it comes to top-performing growth stocks. 
Via The Motley Fool
3 Stocks That Could Be Monster Winners in 2024
Don't be surprised if these three stocks take off in the new year. 
Via The Motley Fool
Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves
In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revealed the company's intent to pursue acquisitions within the $2 billion... 
Via Benzinga
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth... 
Via Benzinga
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up... 
Via Talk Markets
Earnings Scheduled For November 2, 2023
Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million. 
Via Benzinga
Earnings Scheduled For May 9, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
Via Benzinga
Charles Schwab To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Monday
HC Wainwright & Co. cut the price target for 89bio, Inc. (NASDAQ: ETNB) from $27 to $25. HC Wainwright & Co. analyst Ed Arce maintained a Buy rating. 89bio shares fell 5.2% to trade at $11.80 on... 
Via Benzinga
7 Biotech Stocks That Could Be the Next Big Thing
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough. 
Via InvestorPlace
PDS Biotechnology, Pulmonx, Tesla And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Nasdaq Composite dropping around 50 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why These 7 Healthcare Stocks Could Soar in 2023
These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.